Asia Pacific Glaucoma Therapeutics Market Forecast to 2031 - Regional Analysis - by Drug Class, Indication, and Distribution Channel
상품코드:1764892
리서치사:The Insight Partners
발행일:2025년 04월
페이지 정보:영문 137 Pages
라이선스 & 가격 (부가세 별도)
한글목차
아시아태평양의 녹내장 치료제 시장은 2023년에 12억 1,180만 달러로 평가되었고, 2031년에는 15억 9,841만 달러에 이를 것으로 예측되며, 2023년부터 2031년까지의 CAGR은 3.5%를 나타낼 전망입니다.
웨어러블 기술 개발은 아시아태평양의 녹내장 치료제 시장 활성화
기술 혁신은 정확한 진단과 치료 개선의 열쇠가 되는 최신 기기이기 때문에 안과를 포함한 생명 과학의 모든 분야에서 항상 기본이 되고 있습니다. Triggerfish와 같은 혁신적인 콘택트렌즈는 지속적인 안압 추적을 제공합니다. SpyGlass Pharma는 최초의 인간 녹내장 치료 시험의 6개월 데이터를 발표했습니다. 녹내장과 고안압을 앓고있는 환자의 안압을 상당히 낮추고 있음을 보여줍니다.
아시아태평양 녹내장 치료제 시장 개요
아시아태평양의 녹내장 치료제 시장은 중국, 일본, 인도, 호주, 한국 및 기타 아시아태평양으로 세분화됩니다. 진행을 위한 투자의 급증에 기인하고 있습니다. Zhaoke Ophthalmology의 비마토프로스트 티모롤 점안약이 녹내장 치료제으로서 국가 의료품 관리국(NMPA)으로부터 판매 승인을 취득했습니다. STN1011101 점안약에 대해서, NMPA로부터 판매 승인을 취득했습니다. 타플루프로스트 0.0015%와 티몰롤 0.5%를 함유한 이 방부제 프리 제형은 Santen과 AGC Inc.에서 공동 개발했습니다. 이 치료제는 중국에서 녹내장 치료의 미충족 요구에 부응하는 것을 목표로합니다.
2022년 2월 BMC Ophthalmology Journal에 게재된 연구에 따르면 중국은 세계에서 가장 녹내장의 이환율이 높은 것으로 보고되었습니다. 녹내장의 높은 유병률은 향후 질병을 관리하는 치료제의 성장을 가속할 것으로 예측됩니다.
The Asia Pacific glaucoma therapeutics market was valued at US$ 1,211.80 million in 2023 and is expected to reach US$ 1,598.41 million by 2031; it is estimated to register a CAGR of 3.5% from 2023 to 2031.
Development of Wearable Technologies Fuels Asia Pacific Glaucoma Therapeutics Market
Technological innovation has always been fundamental to any discipline of life sciences, including ophthalmology, as modern devices are key to accurate diagnosis and improved treatments. Advancements in treatments have enabled the improved treatment of glaucoma. Wearable glaucoma diagnostics and therapeutics products have emerged as potential solutions. Conventional diagnostic techniques provide reliable intraocular pressure data, while innovative contact lenses such as Sensimed Triggerfish offer continuous IOP tracking. Advanced drug-eluting contact lenses are also emerging as a potential solution for glaucoma therapy. In March 2023, SpyGlass Pharma released 6-month data from its first-in-human glaucoma treatment trial. The data shows that its new drug delivery platform, which is a single-piece, hydrophobic acrylic intraocular lens with drug-eluting pads, continues to significantly lower IOP in patients suffering from glaucoma or ocular hypertension. Thus, the development of such modern wearable products is likely to propel the demand for glaucoma therapeutics in the coming years.
Asia Pacific Glaucoma Therapeutics Market Overview
The glaucoma therapeutics market in Asia Pacific is subsegmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. Market growth in this region is ascribed to the rising incidence of glaucoma, the growing geriatric population, and surging investments to boost research activities. Key market players are adopting strategies such as mergers, acquisitions, product launches, and fundraising to expand their market presence. In February 2023, Zhaoke Ophthalmology's Bimatoprost Timolol eye drops received marketing authorization from the National Medical Products Administration (NMPA) for their use in glaucoma treatment. In February 2023, Santen Pharmaceutical Co., Ltd. received the marketing authorization from the NMPA for its application for STN1011101 eye drops. This preservative-free formulation containing tafluprost 0.0015% and timolol 0.5% was codeveloped by Santen and AGC Inc. The drug aims to address the unmet needs for glaucoma treatment in China.
A study published in the BMC Ophthalmology Journal in February 2022 reported that China has the highest rate of glaucoma in the world. Moreover, the country had 15.58 million people with all types of glaucoma in 2020, and the number is projected to spike up to 25.16 million by 2050. The high prevalence of glaucoma is expected to drive the growth of therapeutics to manage the disease in the future. The glaucoma therapeutics market growth in China is primarily attributed to various growth strategies adopted by market players and the increasing aging population.
Asia Pacific Glaucoma Therapeutics Market Revenue and Forecast to 2031 (US$ Million)
Asia Pacific Glaucoma Therapeutics Market Segmentation
The Asia Pacific glaucoma therapeutics market is categorized into drug class, indication, distribution channel, and country.
Based on drug class, the Asia Pacific glaucoma therapeutics market is segmented into beta blockers, alpha adrenergic agonists, prostaglandins analogues, carbonic anhydrase inhibitors, combination drugs, and others. The prostaglandins analogues segment held the largest market share in 2023.
In terms of indication, the Asia Pacific glaucoma therapeutics market is categorized into open angle glaucoma, angle closure glaucoma, and others. The open angle glaucoma segment held the largest market share in 2023.
By distribution channel, the Asia Pacific glaucoma therapeutics market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment held the largest market share in 2023.
By country, the Asia Pacific glaucoma therapeutics market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific glaucoma therapeutics market share in 2023.
Alcon AG, AbbVie Inc, Bausch & Lomb Inc, LLC, Viatris Inc, Novartis AG, Sun Pharmaceutical Industries Ltd, Teva Pharmaceuticals Industries Ltd, Thea Pharma Inc, and Santen Pharmaceutical Co., Ltd. are among the leading companies operating in the Asia Pacific glaucoma therapeutics market.
Table Of Contents
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macro-economic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country level data:
4. Asia Pacific Glaucoma Therapeutics Market - Key Market Dynamics
